Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma
We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma. CA IX expression in SaOS2 cells cultured under different oxygen tensions was a...
Saved in:
| Published in: | OncoTargets and therapy Vol. 11; pp. 6879 - 6886 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New Zealand
Dove Medical Press Limited
01-01-2018
Taylor & Francis Ltd Dove Medical Press |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma.
CA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry.
Treatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively.
CA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance. |
|---|---|
| AbstractList | Purpose: We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma. Materials and methods: CA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry. Results: Treatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively. Conclusion: CA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance. Keywords: hypoxia, osteosarcoma, carbonic anhydrase IX, inhibitor PURPOSEWe investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma. MATERIALS AND METHODSCA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry. RESULTSTreatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively. CONCLUSIONCA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance. Purpose: We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma. Materials and methods: CA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry. Results: Treatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively. Conclusion: CA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance. We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the expression of CA IX in 27 patients diagnosed with osteosarcoma. CA IX expression in SaOS2 cells cultured under different oxygen tensions was analyzed by Western blotting. To evaluate the effect of CA IX inhibitor, MTS cell viability assay was performed after cells were treated with various concentrations of doxorubicin with or without a CA IX inhibitor. Finally, CA IX expression in patient-derived osteosarcoma samples was evaluated by immunohistochemistry. Treatment with CA IX inhibitor significantly suppressed cell proliferation and migration under hypoxic conditions. CA IX expression was observed in 81% of 27 patients. The 5-year survival rates in patients with high and low stain scores were 43.8% and 81.8%, respectively. CA IX inhibitors have the potential to suppress cell proliferation, migration, and chemoresistance. |
| Audience | Academic |
| Author | Asanuma, Kunihiro Iino, Takahiro Okuno, Kazuma Nakamura, Tomoki Kakimoto, Takuya Sudo, Akihiro Matsubara, Takao Matsumine, Akihiko |
| AuthorAffiliation | 2 Department of Orthopedic Surgery, Ise Red Cross Hospital, Ise, Japan, qsghp572@yahoo.co.jp 3 Department of Orthopedic Surgery, Fukui University Graduate School of Medicine, Fukui, Japan 1 Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp |
| AuthorAffiliation_xml | – name: 2 Department of Orthopedic Surgery, Ise Red Cross Hospital, Ise, Japan, qsghp572@yahoo.co.jp – name: 1 Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – name: 3 Department of Orthopedic Surgery, Fukui University Graduate School of Medicine, Fukui, Japan |
| Author_xml | – sequence: 1 givenname: Kazuma surname: Okuno fullname: Okuno, Kazuma email: qsghp572@yahoo.co.jp, qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Ise Red Cross Hospital, Ise, Japan, qsghp572@yahoo.co.jp – sequence: 2 givenname: Takao surname: Matsubara fullname: Matsubara, Takao email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – sequence: 3 givenname: Tomoki surname: Nakamura fullname: Nakamura, Tomoki email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – sequence: 4 givenname: Takahiro surname: Iino fullname: Iino, Takahiro email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – sequence: 5 givenname: Takuya surname: Kakimoto fullname: Kakimoto, Takuya email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – sequence: 6 givenname: Kunihiro surname: Asanuma fullname: Asanuma, Kunihiro email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp – sequence: 7 givenname: Akihiko surname: Matsumine fullname: Matsumine, Akihiko email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Fukui University Graduate School of Medicine, Fukui, Japan – sequence: 8 givenname: Akihiro surname: Sudo fullname: Sudo, Akihiro email: qsghp572@yahoo.co.jp organization: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan, qsghp572@yahoo.co.jp |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30349321$$D View this record in MEDLINE/PubMed |
| BookMark | eNptksuLFDEQxoOsuA89eZcGQYRlxrw66VyEZfCxsLAHR_AiIZOuTGfpTsakW9j_3jQ77s6I5JBQ9asvVNV3jk5CDIDQa4KXlHD54Xa9Xn4jUgpcP0NnhMhmIRTDJwfvU3Se8x3GQjSUv0CnDDOuGCVn6OfKpE0M3lYmdPdtMhmq6x8VhM4EC7kapyGmykLfV7sUe-8gmdHHUPB2nyzxbYKc56gPVcwjxGySjYN5iZ4702d4tb8v0PfPn9arr4ub2y_Xq6ubha2xHBeqYbamlEtKGuVc23BueNMS6YjbSKOM5UTVVBkGDKgDhoUVljfMUGg3INkF-vigu5s2A7QWwphMr3fJDybd62i8Ps4E3-lt_K0FUVhQVQTe7wVS_DVBHvXg89y1CRCnrCmhQmFec17Qt_-gd3FKobSnSwu0VgTX4onamh60Dy6Wf-0sqq_qhglVEzJTy_9Q5bQweFvW7HyJHxW8OyjowPRjl2M_zSvJx-DlA2hTzDmBexwGwXq2jS620XvbFPrN4fwe2b8-YX8Ag0O-ew |
| CitedBy_id | crossref_primary_10_1016_j_ejmech_2023_115538 crossref_primary_10_3390_ph13090252 crossref_primary_10_1186_s12885_020_06784_7 crossref_primary_10_3390_ijms222011119 crossref_primary_10_1007_s13318_024_00903_6 crossref_primary_10_1002_ange_202002748 crossref_primary_10_1002_anie_202002748 crossref_primary_10_18632_aging_205941 crossref_primary_10_1039_D4MD00302K crossref_primary_10_3390_cells9091998 crossref_primary_10_3390_cancers14061482 crossref_primary_10_1038_s41416_020_01107_w crossref_primary_10_3390_ijms242015474 crossref_primary_10_1080_14756366_2022_2056734 crossref_primary_10_1097_CAD_0000000000000799 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Dove Medical Press Limited 2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 Okuno et al. This work is published and licensed by Dove Medical Press Limited 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 Dove Medical Press Limited – notice: 2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 Okuno et al. This work is published and licensed by Dove Medical Press Limited 2018 |
| DBID | NPM AAYXX CITATION 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K9. LK8 M0S M2O M7P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.2147/OTT.S177605 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Research Library Biological Science Database Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1178-6930 |
| EndPage | 6886 |
| ExternalDocumentID | A583695116 10_2147_OTT_S177605 30349321 |
| Genre | Journal Article |
| GeographicLocations | United Kingdom--UK United States--US Japan |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US – name: Japan |
| GroupedDBID | --- 0YH 29N 2WC 53G 5VS 7X7 8FE 8FH 8FI 8FJ 8G5 ABDBF ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RNS RPM TR2 TUS UKHRP VDV AAYXX CITATION TDBHL 3V. 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c507t-983c522472189ffd844a48d17f1fb7a9ac419529a3e3e2fe306c6c483a2edbe73 |
| IEDL.DBID | RPM |
| ISSN | 1178-6930 |
| IngestDate | Tue Sep 17 21:23:34 EDT 2024 Sat Aug 17 03:48:11 EDT 2024 Tue Nov 05 16:23:22 EST 2024 Tue Nov 19 21:06:45 EST 2024 Tue Nov 12 23:26:24 EST 2024 Tue Aug 20 22:14:23 EDT 2024 Thu Nov 21 22:25:45 EST 2024 Wed Oct 16 00:59:17 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | hypoxia carbonic anhydrase IX inhibitor osteosarcoma |
| Language | English |
| License | The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c507t-983c522472189ffd844a48d17f1fb7a9ac419529a3e3e2fe306c6c483a2edbe73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1099-7436 0000-0003-0474-4368 0000-0002-1244-0236 0000-0003-3591-418X |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190629/ |
| PMID | 30349321 |
| PQID | 2242591056 |
| PQPubID | 3933336 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6190629 proquest_miscellaneous_2126904544 proquest_journals_2242591056 gale_infotracmisc_A583695116 gale_infotracacademiconefile_A583695116 gale_healthsolutions_A583695116 crossref_primary_10_2147_OTT_S177605 pubmed_primary_30349321 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | OncoTargets and therapy |
| PublicationTitleAlternate | Onco Targets Ther |
| PublicationYear | 2018 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Medical Press |
| References | 20461082 - Br J Cancer. 2010 May 25;102(11):1627-35 11751418 - Cancer Res. 2001 Dec 15;61(24):8924-9 11156414 - Cancer Res. 2000 Dec 15;60(24):7075-83 16996620 - Trends Pharmacol Sci. 2006 Nov;27(11):566-73 16175178 - Nat Rev Cancer. 2005 Oct;5(10):786-95 10637570 - Mol Med Today. 2000 Jan;6(1):15-9 10688890 - Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 21363891 - J Cell Sci. 2011 Apr 1;124(Pt 7):1077-87 29786141 - Int J Cancer. 2018 Oct 15;143(8):2065-2075 15556624 - FEBS Lett. 2004 Nov 19;577(3):439-45 14712082 - Cell Cycle. 2004 Feb;3(2):164-7 19240720 - Br J Cancer. 2009 Mar 24;100(6):874-80 20519553 - J Pharmacol Exp Ther. 2010 Sep 1;334(3):710-9 18180112 - Pathol Res Pract. 2008;204(3):175-83 9665489 - Am J Pathol. 1998 Jul;153(1):279-85 24101905 - Front Physiol. 2013 Oct 01;4:271 12171890 - Clin Cancer Res. 2002 Aug;8(8):2595-604 11953885 - Br J Cancer. 2002 Apr 22;86(8):1276-82 8239534 - Anticancer Res. 1993 Sep-Oct;13(5A):1549-56 26357839 - Expert Opin Ther Targets. 2015;19(12):1593-605 22289741 - Oncotarget. 2012 Jan;3(1):84-97 23914349 - Front Oncol. 2013 Jul 29;3:199 20735983 - Biochem Biophys Res Commun. 2010 Oct 1;400(4):493-9 20822935 - Urol Oncol. 2012 Jul-Aug;30(4):463-8 10573225 - Eur Respir J. 1999 Oct;14(4):806-11 10362108 - Br J Cancer. 1999 Jun;80(7):1005-11 12865916 - Br J Cancer. 2003 Jul 21;89(2):271-6 11691824 - Cancer Res. 2001 Nov 1;61(21):7992-8 14567991 - Exp Cell Res. 2003 Nov 1;290(2):332-45 21415165 - Cancer Res. 2011 May 1;71(9):3364-76 17415526 - Cancer Metastasis Rev. 2007 Jun;26(2):299-310 20857482 - J Cell Physiol. 2011 Feb;226(2):299-308 17103226 - Virchows Arch. 2006 Dec;449(6):673-81 24409151 - Front Physiol. 2014 Jan 08;4:400 9099966 - Br J Cancer. 1997;75(8):1167-72 |
| References_xml | |
| SSID | ssj0066824 |
| Score | 2.1613867 |
| Snippet | We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also evaluated the... Purpose: We investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also... PURPOSEWe investigated the effect of carbonic anhydrase IX (CA IX) inhibitor under hypoxia and normoxia in SaOS2 human osteosarcoma cell line. We also... |
| SourceID | pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 6879 |
| SubjectTerms | Analysis Anthracyclines Bone cancer Bone surgery Breast cancer Cancer therapies Carbonic anhydrases Cell adhesion & migration Cell culture Cell cycle Cell growth Cell viability Chemotherapy Development and progression Health aspects Hypoxia Immunohistochemistry Medical prognosis Metastasis Original Research Orthopedics Osteosarcoma Proteins Sarcoma Tumors |
| Title | Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30349321 https://www.proquest.com/docview/2242591056 https://search.proquest.com/docview/2126904544 https://pubmed.ncbi.nlm.nih.gov/PMC6190629 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCaWHopehr2Xrds0oMBOTvyQLPlYZC26Q4cB3YBeBkOSJSRAIwd5HPbvR1p2UO-4MylDpkjro0x-ArgwRsjUG544LgUlKCJRmpeJ99o1qamMtXQ0cHMnv9-rr1dEkyOGXpiuaN-a1Sw8rGdhtexqKzdrOx_qxOY_bhcI-tMyr-YTmCA2HFL0-PktS5Xz2IhHV_DMMTGe3WVSImw_g9OC6FiKPBvtQv9-ix9tRuNCyUc7z_UzeNpDRnYZp_YcnrjwAk5v-5_iL-H3Qm8NMdwyHZZ_mi3uS-zbPXNhSSu6Y_vDut0yOqFnG7qjx7u46qje9MKuSisydLBVYNT40e4wBNq1fgW_rq9-Lm6S_taExCK22yeVKiyCKo6pnaq8bxTnmqsmkz7zRupKW55VIq904QqXe4c5gy0tV4XOXWOcLF7DSWiDewuskUWJ-ZlIbWW4EUYZZ3TqnbcuRe1yCheDFetNJMeoMakgu9do97q3-xQ-kYXr2Nl5DKn6Uih8PiI-fNCXToOCCg1tdd8bgNMgeqqR5vlIE4PBjsXDKtZ9MO7qnNIqhEUCxZ-PYhpJBWbBtQfUyfKyIjpCPoU3cdGPrzQ4zRTkyB2OCkTRPZag53ZU3b2nvvvvke_hDCGaioc-53Cy3x7cB5jsmsPHzu3_AuyNCps |
| link.rule.ids | 230,315,729,782,786,887,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbWDuh66d5tum7VgAI7OfFDsuRjkbVIsaYY0A7oZTAkWUICLHaQx2H_fqQfQb1jz6QF2SQlfjL5CeDCGCFDb3jguBQEUESgNE8D77UrQpMZa-loYHIv7x7V9yuiyRFdL0xdtG_NfFj-WQzL-ayurVwu7KirExv9nI4x6Q_TOBvtwUuM1zDsQHqzAKepinnTikeX8IwQGg_vIykxcT-Eg4QIWZI46u1D_6_GT7ajfqnkk73n-vUzZ_0Gjtpkk1024rfwwpXv4GDa_k5_D7_HemWIG5fpcva3WOGOxm4emStn5AtrttkuqhWjs322pNt9vGv8BdWLVljXdzXcHmxeMmoZqdYYPNVCf4Bf11cP40nQ3rcQWMwKN0GmEovpGEdQqDLvC8W55qqIpI-8kTrTlkeZiDOduMTF3iHasKnlKtGxK4yTyUfYL6vSnQArZJIishOhzQw3wijjjA6989aFqJ0O4KL7-vmyodXIEY6QvXK0V97aawDnZJm86QndBWN-KRSOj7kiDvSt1qBwRANZ3XYV4DSI2KqnedbTxDCyfXFn_bwN43UeEyDDhEqg-OtOTE9SaVrpqi3qRHGaEZEhH8Bx4yy7V-qcbQCy50Y7BSL37kvQe2qS79ZbTp_95Dm8mjxMb_Pbm7sfn-AQEz3VHB2dwf5mtXWfYW9dbL_UofMPApggJA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxwxDBZNCksufTfZNmlcCPQ0Oy_P2HMMmywJbUIgLeRSBttjswvZmWUfh_77SvMi02Nzlmw8SLIkj_QJ4EzrRAROc89ykVCCknhS8dRzTtki0Jk2hp4Gru7F7YO8uCSYnH7UV120b_RiUj4uJ-ViXtdWrpbG7-rE_LubKQb9QRpl_qpw_h68RJsNoi5Rby7hNJURb9rxaBCPj-nx5D4UAoP3AxjFBMoSR-HAF_17Iz9xScNyySf-Z_b6GSd_A6_aoJOdNyxv4YUt38Hopv2t_h5-T9VaE0YuU-X8T7FGz8auH5gt56QTG7bdLas1ozd-tqIpP842eoPsRUus67wajA-2KBm1jlQbNKJqqT7Ar9nlz-mV185d8AxGh1svk7HBsIxjcigz5wrJueKyCIULnRYqU4aHWRJlKraxjZzFrMOkhstYRbbQVsQfYb-sSnsErBBxihleEphMc51oqa1WgbPO2AC50zGcdRLIVw28Ro5pCcksR5nlrczGcErSyZve0N4o8_NE4v4YM-JG32oOMksUklFtdwEegwCuBpzHA040JzMkdxqQt-a8ySNKzDCwSpD8tSfTSipRK221Q54wSjMCNORjOGwUpv-kTuHGIAaq1DMQyPeQghpUg323GvPpv1eewujuYpb_uL79_hkOMN6TzQvSMexv1zt7AnubYveltp6__lMipA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carbonic+anhydrase+IX+enhances+tumor+cell+proliferation+and+tumor+progression+in+osteosarcoma&rft.jtitle=OncoTargets+and+therapy&rft.au=Okuno%2C+Kazuma&rft.au=Matsubara%2C+Takao&rft.au=Nakamura%2C+Tomoki&rft.au=Iino%2C+Takahiro&rft.date=2018-01-01&rft.pub=Taylor+%26+Francis+Ltd&rft.eissn=1178-6930&rft.volume=11&rft.spage=6879&rft_id=info:doi/10.2147%2FOTT.S177605&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6930&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6930&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6930&client=summon |